Kezar Life Sciences, Inc. (NASDAQ: KZR)

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases with high unmet medical need. The company focuses on the immunoproteasome as a validated target for regulating inflammatory disease processes across multiple autoimmune conditions. Its lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor being developed for autoimmune hepatitis and other immune-mediated disorders.

Kezar Life Sciences, Inc. generates revenue primarily through collaboration and license agreements with third parties. The company has received upfront payments and is entitled to potential milestone and royalty payments under its agreements with Onyx Therapeutics and Everest Medicines. Revenue is derived from licensing its intellectual property related to zetomipzomib for development and commercialization in specified territories.

The company operates through the following segments:

• Research and development segment includes activities related to the discovery, preclinical testing, and clinical development of product candidates such as zetomipzomib and KZR-261.

• Business development and licensing segment encompasses negotiations, management, and execution of collaboration and license agreements with partners like Onyx and Everest.

Kezar Life Sciences, Inc. operates in a competitive biotechnology landscape focused on immunoproteasome-targeted therapies for autoimmune diseases. The company differentiates itself through its first-in-class selective immunoproteasome inhibitor, zetomipzomib, which has demonstrated steroid-sparing clinical activity in autoimmune hepatitis patients refractory to standard care. Its competitive advantages include a broad immunomodulatory mechanism, subcutaneous weekly dosing, and a favorable safety profile observed in clinical trials.

Kezar Life Sciences, Inc. serves patients suffering from immune-mediated diseases such as autoimmune hepatitis, systemic lupus erythematosus, and lupus nephritis. The company collaborates with healthcare providers, clinical trial sites, and third-party payors to advance its product candidates through development and potential commercialization pathways.